Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 224-230

  Shi, Lin ^a   Song, Quansheng ^b,c   Zhang, Yingmei ^b,c   Lou, Yaxin ^c   Wang, Yanfang ^a   Tian, Linjie ^b,c   Zheng, Yi ^b,c   Ma, Dalong ^b,c   Ke, Xiaoyan ^a   Wang, Ying ^b,c  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antitumor; Chemotherapy; In vivo; K562; rhPDCD5 protein

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; IDARUBICIN; IMATINIB; RECOMBINANT PROGRAMMED CELL DEATH 5 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; FEMALE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ARA;

EID: 77952741557     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.068     Document Type: Article

References (22)

1. Goldman J.M., and Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349 (2003) 1451-1464
2. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340 (1999) 1330-1340
3. Druker B.J. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin. Pharmacother. 4 (2003) 963-971
4. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 (2003) 994-1004
5. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
6. Liu H., Wang Y., Zhang Y., et al. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem. Biophys. Res. Commun. 254 (1999) 203-210
7. Wang Y., Li X., Wang L., et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J. Cell Sci. 117 (2004) 1525-1532
8. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
9. Li H., Wang Q., Gao F., et al. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol. Rep. 20 (2008) 573-579
10. Ma X., Ruan G., Wang Y., et al. Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5′ regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population. Clin. Cancer Res. 11 (2005) 8592-8599
11. Ruan G.R., Qin Y.Z., Chen S.S., et al. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk. Res. 30 (2006) 1159-1165
12. Spinola M., Meyer P., Kammerer S., et al. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J. Clin. Oncol. 24 (2006) 1672-1678
13. Xu X.R., Huang J., Xu Z.G., et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl. Acad. Sci. USA 98 (2001) 15089-15094
14. Yang Y.H., Zhao M., Li W.M., et al. Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis 11 (2006) 993-1001
15. Chen L.N., Wang Y., Ma D.L., and Chen Y.Y. Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis 11 (2006) 101-111
16. Rui M., Chen Y., Zhang Y., and Ma D. Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Life Sci. 71 (2002) 1771-1778
17. Wang Y., Li D., Fan H., et al. Cellular uptake of exogenous human PDCD5 protein. J. Biol. Chem. 281 (2006) 24803-24817
18. Ruan G.R., Zhao H.S., Chang Y., et al. Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo. Apoptosis 13 (2008) 641-648
19. Leader B., Baca Q.J., and Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008) 21-39
20. Plum S.M., Hanson A.D., Volker K.M., et al. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin. Cancer Res. 9 (2003) 4619-4626
21. Fulda S., Wick W., Weller M., and Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8 (2002) 808-815
22. Zhou Y., Du W., Koretsky T., et al. TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 112 (2008) 2474-2483